X

Drug Profile

EscharEx - MediWound

Alternative Names: EscharEx; EX-02

Latest Information Update: 02 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MediWound
Class Antineoplastics; Enzymes; Foot disorder therapies; Skin disorder therapies
Mechanism of Action Peptide hydrolase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Wounds
Phase II Diabetic foot ulcer; Leg ulcer
Phase I/II Basal cell cancer

Most Recent Events

26 Nov 2024 MediWound plans to submit IND for phase III trial for Venous leg ulcers by year-end
15 Nov 2024 MediWound plans a phase II trial for Leg ulcer in USA and Poland (NCT06690177)
13 Nov 2024 Phase-III clinical trials in Wounds (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com